Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
About this item
Full title
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2023-01, Vol.388 (1), p.44-54
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with cetuximab, an epidermal growth factor receptor antibody.
Alternative Titles
Full title
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9908297
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9908297
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2212419
